These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21233194)

  • 1. Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor.
    Liapi E; Geschwind JF; Vali M; Khwaja AA; Prieto-Ventura V; Buijs M; Vossen JA; Ganapathy-Kanniappan S; Wahl RL
    J Nucl Med; 2011 Feb; 52(2):225-30. PubMed ID: 21233194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model.
    Park HS; Chung JW; Jae HJ; Kim YI; Son KR; Lee MJ; Park JH; Kang WJ; Yoon JH; Chung H; Lee K
    Korean J Radiol; 2007; 8(3):216-24. PubMed ID: 17554189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer.
    Vali M; Liapi E; Kowalski J; Hong K; Khwaja A; Torbenson MS; Georgiades C; Geschwind JF
    J Vasc Interv Radiol; 2007 Jan; 18(1 Pt 1):95-101. PubMed ID: 17296709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic intra-arterial injection of 3-bromopyruvate in rabbit VX2 tumor.
    Shin SW; Han H; Choo SW; Yoo BC; Park CK; Do YS; Lee JH; Lee DH; Choi D; Choo IW; Kim SS; Lee JY
    Acta Radiol; 2006 Dec; 47(10):1036-41. PubMed ID: 17135005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study.
    Vali M; Vossen JA; Buijs M; Engles JM; Liapi E; Ventura VP; Khwaja A; Acha-Ngwodo O; Ganapathy-Kanniappan S; Syed L; Wahl RL; Geschwind JF
    J Pharmacol Exp Ther; 2008 Oct; 327(1):32-7. PubMed ID: 18591216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model.
    Jae HJ; Chung JW; Park HS; Lee MJ; Lee KC; Kim HC; Yoon JH; Chung H; Park JH
    Korean J Radiol; 2009; 10(6):596-603. PubMed ID: 19885316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits.
    Okuma T; Matsuoka T; Okamura T; Wada Y; Yamamoto A; Oyama Y; Koyama K; Nakamura K; Watanabe Y; Inoue Y
    J Nucl Med; 2006 Aug; 47(8):1351-8. PubMed ID: 16883016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET evaluation of therapeutic effects on VX2 liver tumor.
    Oya N; Nagata Y; Tamaki N; Takagi T; Murata R; Magata Y; Abe M; Konishi J
    J Nucl Med; 1996 Feb; 37(2):296-302. PubMed ID: 8667065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model.
    Song SL; Liu JJ; Huang G; Wang ZH; Song YY; Sun XG; Chen T
    J Nucl Med; 2008 Feb; 49(2):303-9. PubMed ID: 18199614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization.
    Vossen JA; Buijs M; Syed L; Kutiyanwala F; Kutiyanwala M; Geschwind JF; Vali M
    Clin Exp Metastasis; 2008; 25(7):811-7. PubMed ID: 18649116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma.
    Song MJ; Bae SH; Yoo IeR; Park CH; Jang JW; Chun HJ; Choi BG; Lee HG; Choi JY; Yoon SK
    World J Gastroenterol; 2012 Jul; 18(25):3215-22. PubMed ID: 22783045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of experimental liver tumors using fluorine-18-2-fluoro-2-deoxy-D-glucose PET.
    Oya N; Nagata Y; Ishigaki T; Abe M; Tamaki N; Magata Y; Konishi J
    J Nucl Med; 1993 Dec; 34(12):2124-9. PubMed ID: 8254399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
    Tatsumi M; Nakamoto Y; Traughber B; Marshall LT; Geschwind JF; Wahl RL
    Cancer Res; 2003 Oct; 63(19):6252-7. PubMed ID: 14559811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of intra-arterial infusion of 3-bromopyruvate on metastases and survival benefit of hepatic VX2 tumor in rabbits].
    Jiang XY; Zhang XP; Huang JH; Luo RG; Miao BJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(39):3139-42. PubMed ID: 24417996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferret thoracic anatomy by 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (18F-FDG PET/CT) imaging.
    Wu A; Zheng H; Kraenzle J; Biller A; Vanover CD; Proctor M; Sherwood L; Steffen M; Ng C; Mollura DJ; Jonsson CB
    ILAR J; 2012; 53(1):E9-21. PubMed ID: 23382267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposome contrast agent for CT-based detection and localization of neoplastic and inflammatory lesions in rabbits: validation with FDG-PET and histology.
    Zheng J; Allen C; Serra S; Vines D; Charron M; Jaffray DA
    Contrast Media Mol Imaging; 2010; 5(3):147-54. PubMed ID: 20586032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.
    Cochet A; Pigeonnat S; Khoury B; Vrigneaud JM; Touzery C; Berriolo-Riedinger A; Dygai-Cochet I; Toubeau M; Humbert O; Coudert B; Fumoleau P; Arnould L; Brunotte F
    J Nucl Med; 2012 Apr; 53(4):512-20. PubMed ID: 22343501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology.
    Hyafil F; Cornily JC; Rudd JH; Machac J; Feldman LJ; Fayad ZA
    J Nucl Med; 2009 Jun; 50(6):959-65. PubMed ID: 19443582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.